TY - JOUR
T1 - Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy
T2 - The CRIC (Chronic Renal Insufficiency Cohort) Study
AU - CRIC Study Investigators
AU - Mehta, Rupal
AU - Cai, Xuan
AU - Lee, Jungwha
AU - Xie, Dawei
AU - Wang, Xue
AU - Scialla, Julia
AU - Anderson, Amanda H.
AU - Taliercio, Jon
AU - Dobre, Mirela
AU - Chen, Jing
AU - Fischer, Michael
AU - Leonard, Mary
AU - Lash, James
AU - Hsu, Chi yuan
AU - de Boer, Ian H.
AU - Feldman, Harold I.
AU - Wolf, Myles
AU - Isakova, Tamara
AU - Appel, Lawrence J.
AU - Go, Alan S.
AU - He, Jiang
AU - Rao, Panduranga S.
AU - Rahman, Mahboob
AU - Townsend, Raymond R.
N1 - Funding Information:
This study was supported by grants P30DK114857 , R01DK081374 (Dr Wolf), K24DK093723 (Dr Wolf), R01DK102438 (Dr Isakova), R01DK111952 (Dr Scialla), National Kidney Foundation of Illinois Young Investigator Grant (Dr Mehta), and a Strategically Focused Research Network Center Grant from the American Heart Association (Drs Wolf and Isakova). Research reported in this publication was also supported in part by the National Institutes of Health 's (NIH’s) National Center for Advancing Translational Sciences (NCATS), grant number KL2TR001424 . Funding for the CRIC Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases ( U01DK060990 , U01DK060984 , U01DK061022 , U01DK061021 , U01DK061028 , U01DK060980 , U01DK060963 , and U01DK060902 ). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award (CTSA) NIH / NCATS UL1TR000003 , Johns Hopkins University UL1TR-000424 , University of Maryland GCRC M01 RR-16500 , Clinical and Translational Science Collaborative of Cleveland , UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433 , University of Illinois at Chicago CTSA UL1RR029879 , Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036 , and Kaiser Permanente NIH / NCRR UCSF-CTSI UL1 RR-024131 . The funders had no role in the study design; data collection, analysis, or reporting; or the decision to submit for publication.
Funding Information:
Dr Mehta has interest in Abbot Laboratories, AbbVie, Inc, and Teva Pharmaceuticals Industries Ltd. Dr Isakova has received honoraria from Bayer and grant support from Shire. Dr Wolf has received research support, honoraria, or consultant fees from Akebia, Amag, Amgen, Ardelyx, DiaSorin, Keryx, and Shire. The remaining authors declare that they have no relevant financial interests.
Funding Information:
Lawrence J. Appel, MD, MPH, Alan S. Go, MD, Jiang He, MD, PhD, Panduranga S. Rao, MD, Mahboob Rahman, MD, Raymond R. Townsend, MD. Rupal Mehta, MD, Xuan Cai, MS, Jungwha Lee, PhD, Dawei Xie, PhD, Xue Wang, MS, Julia Scialla, MD, MHS, Amanda H. Anderson, PhD, MPH, Jon Taliercio, DO, Mirela Dobre, MD, Jing Chen, MD, MMSc, MSc, Michael Fischer, MD, MSPH, Susan Steigerwalt, MD, Mary Leonard, MD, MSCE, James Lash, MD, Chi-yuan Hsu, MD, MSc, Ian H. de Boer, MD, MS, Harold I. Feldman, MD, MSCE, Myles Wolf, MD, MMSc, and Tamara Isakova, MD, MMSc. Conception and design: RM, MW, TI; acquisition of data: RM, XC, JL, DX, XW, JT, JC, SS, ML, JL, CH, IHD, HIF, MW, TI; analysis and interpretation of data: RM, XC, JL, DX, XW, JS, AHA, JT, MD, JC, MF, SS, ML, JL, C-yH, IHdB, HIF, MW, TI. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. This study was supported by grants P30DK114857, R01DK081374 (Dr Wolf), K24DK093723 (Dr Wolf), R01DK102438 (Dr Isakova), R01DK111952 (Dr Scialla), National Kidney Foundation of Illinois Young Investigator Grant (Dr Mehta), and a Strategically Focused Research Network Center Grant from the American Heart Association (Drs Wolf and Isakova). Research reported in this publication was also supported in part by the National Institutes of Health's (NIH's) National Center for Advancing Translational Sciences (NCATS), grant number KL2TR001424. Funding for the CRIC Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award (CTSA) NIH/NCATS UL1TR000003, Johns Hopkins University UL1TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, and Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131. The funders had no role in the study design; data collection, analysis, or reporting; or the decision to submit for publication. Dr Mehta has interest in Abbot Laboratories, AbbVie, Inc, and Teva Pharmaceuticals Industries Ltd. Dr Isakova has received honoraria from Bayer and grant support from Shire. Dr Wolf has received research support, honoraria, or consultant fees from Akebia, Amag, Amgen, Ardelyx, DiaSorin, Keryx, and Shire. The remaining authors declare that they have no relevant financial interests. The authors thank the participants, investigators, and staff of the CRIC Study for their time and commitment. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the position or policy of the Department of Veterans Affairs or the US government. Received February 8, 2019. Evaluated by 3 external peer reviewers and a statistician, with editorial input from an Acting Editor-in-Chief (Editorial Board Member Bradley A. Warady, MD). Accepted in revised form September 16, 2019. The involvement of an Acting Editor-in-Chief to handle the peer-review and decision-making processes was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Publisher Copyright:
© 2019 National Kidney Foundation, Inc.
PY - 2020/6
Y1 - 2020/6
N2 - Rationale & Objective: Studies using a single measurement of fibroblast growth factor 23 (FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for requirement for kidney replacement therapy (KRT) in patients with chronic kidney disease. However, the data do not account for changes in FGF-23 levels as kidney disease progresses. Study Design: Case-cohort study. Setting & Participants: To evaluate the association between serial FGF-23 levels and risk for requiring KRT, our primary analysis included 1,597 individuals in the Chronic Renal Insufficiency Cohort Study who had up to 5 annual measurements of carboxy-terminal FGF-23. There were 1,135 randomly selected individuals, of whom 266 initiated KRT, and 462 individuals who initiated KRT outside the random subcohort. Exposure: Serial FGF-23 measurements and FGF-23 trajectory group membership. Outcomes: Incident KRT. Analytical Approach: To handle time-dependent confounding, our primary analysis of time-updated FGF-23 levels used time-varying inverse probability weighting in a discrete time failure model. To compare our results with prior data, we used baseline and time-updated FGF-23 values in weighted Cox regression models. To examine the association of FGF-23 trajectory subgroups with risk for incident KRT, we used weighted Cox models with FGF-23 trajectory groups derived from group-based trajectory modeling as the exposure. Results: In our primary analysis, the HR for the KRT outcome per 1 SD increase in the mean of natural log–transformed (ln)FGF-23 in the past was 1.94 (95% CI, 1.51-2.49). In weighted Cox models using baseline and time-updated values, elevated FGF-23 level was associated with increased risk for incident KRT (HRs per 1 SD ln[FGF-23] of 1.18 [95% CI, 1.02-1.37] for baseline and 1.66 [95% CI, 1.49-1.86] for time-updated). Membership in the slowly and rapidly increasing FGF-23 trajectory groups was associated with ∼3- and ∼21-fold higher risk for incident KRT compared to membership in the stable FGF-23 trajectory group. Limitations: Residual confounding and lack of intact FGF-23 values. Conclusions: Increasing FGF-23 levels are independently associated with increased risk for incident KRT.
AB - Rationale & Objective: Studies using a single measurement of fibroblast growth factor 23 (FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for requirement for kidney replacement therapy (KRT) in patients with chronic kidney disease. However, the data do not account for changes in FGF-23 levels as kidney disease progresses. Study Design: Case-cohort study. Setting & Participants: To evaluate the association between serial FGF-23 levels and risk for requiring KRT, our primary analysis included 1,597 individuals in the Chronic Renal Insufficiency Cohort Study who had up to 5 annual measurements of carboxy-terminal FGF-23. There were 1,135 randomly selected individuals, of whom 266 initiated KRT, and 462 individuals who initiated KRT outside the random subcohort. Exposure: Serial FGF-23 measurements and FGF-23 trajectory group membership. Outcomes: Incident KRT. Analytical Approach: To handle time-dependent confounding, our primary analysis of time-updated FGF-23 levels used time-varying inverse probability weighting in a discrete time failure model. To compare our results with prior data, we used baseline and time-updated FGF-23 values in weighted Cox regression models. To examine the association of FGF-23 trajectory subgroups with risk for incident KRT, we used weighted Cox models with FGF-23 trajectory groups derived from group-based trajectory modeling as the exposure. Results: In our primary analysis, the HR for the KRT outcome per 1 SD increase in the mean of natural log–transformed (ln)FGF-23 in the past was 1.94 (95% CI, 1.51-2.49). In weighted Cox models using baseline and time-updated values, elevated FGF-23 level was associated with increased risk for incident KRT (HRs per 1 SD ln[FGF-23] of 1.18 [95% CI, 1.02-1.37] for baseline and 1.66 [95% CI, 1.49-1.86] for time-updated). Membership in the slowly and rapidly increasing FGF-23 trajectory groups was associated with ∼3- and ∼21-fold higher risk for incident KRT compared to membership in the stable FGF-23 trajectory group. Limitations: Residual confounding and lack of intact FGF-23 values. Conclusions: Increasing FGF-23 levels are independently associated with increased risk for incident KRT.
KW - CKD progression
KW - Chronic kidney disease (CKD)
KW - biomarker
KW - dialysis
KW - disease trajectory
KW - end-stage renal disease (ESRD)
KW - fibroblast growth factor 23 (FGF-23)
KW - kidney failure
KW - kidney function decline
KW - renal replacement therapy (RRT)
KW - transplant
UR - http://www.scopus.com/inward/record.url?scp=85076576049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076576049&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2019.09.009
DO - 10.1053/j.ajkd.2019.09.009
M3 - Article
C2 - 31864822
AN - SCOPUS:85076576049
SN - 0272-6386
VL - 75
SP - 908
EP - 918
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -